Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
See you in Barcelona or online to network with colleagues and debate on burning topics in the field
Shape the future of cancer drug development and be part of this unique forum gathering the key actors in field
Keep up to date with practice-changing publications in non-small-cell lung cancer and advanced urothelial cancer by joining this in-depth analysis with leading experts
Application deadline extended: Apply by 10 September!
Submit your application by 17 September!
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers.
Findings from the ProBio study
Evidence for efficacy is based on the results from the RUBY study
Findings from the largest meningioma cohort including a prospective set from the RTOG-0539 study
The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world
HIV-associated lymphomas are not just lymphomas: EHA–ESMO CPG on diagnosis, treatment and follow-up of lymphomas in people who are HIV positive
At the ESMO Congress 2024, the ESMO Women for Oncology (W4O) Committee is presenting new findings on female representation in leadership positions
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The combination is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy
Findings from the ProBio study
Evidence for efficacy is based on the results from the RUBY study
Findings from the largest meningioma cohort including a prospective set from the RTOG-0539 study
The combination is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy
Findings from the HERB study
Findings from the LITESPARK-005 study
Evidence for efficacy is based on the results from the INDIGO study
It is intended for the treatment of CLDN18.2-positive gastric or gastro-oesophageal junction adenocarcinoma
Findings from the TURBO-NSCLC study
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers.
The ESMO Congress 2024 will take place from September 13-17 in Barcelona, bringing together participants from all over the world
Treatment of gastrointestinal (GI) cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment
Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress 2024
The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress 2024, the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract
The ESMO Gynaecological Cancers Congress 2024 will be held in Florence, Italy, between 20-22 June, hosting international experts who will present and discuss the latest developments in the biology, diagnosis and therapy of gynaecological tumours
Ahead of World No Tobacco Day 2024, European scientific, healthcare professional and other civil society organisations call for an EU Endgame on Tobacco
First global study in young women with high-risk genes and a pregnancy after breast cancer shows Assisted Reproductive Techniques (ART) are safe, with no increase in breast cancer recurrence
ESMO Breast Cancer 2024 will be held in Berlin, Germany, between 15-17 May where the latest research in breast cancer will be presented
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)
The recipients of the 2024 ESMO Society Awards have been announced today by ESMO
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Tom Powles, Editor in Chief of ESMO’s flagship journal Annals of Oncology; Solange Peters, ESMO Past President; and Fabrice André, President Elect of the Society have been recognised as leading and influential researchers for their remarkable achievements in cancer care
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
At the ESMO Congress 2024, the ESMO Women for Oncology (W4O) Committee is presenting new findings on female representation in leadership positions
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
Recent research shows that tailored strategies and political commitment can revert current epidemiology trends of cancer
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
With a recent survey in collaboration with SIOPE and the recognition of LGBTQ as a specific patient population in the recommendations for a Global Curriculum in Medical Oncology, ESMO is at the forefront of a more inclusive oncology
The use of sunscreens is essential to protect the skin from UV exposure, but they may enter waterways damaging the ecosystem
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Spain
Portugal
Portugal
Republic of Singapore
United Kingdom
Spain
France
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
